The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

• Published in: Nutrition, metabolism, and cardiovascular diseases Vol. 35; no. 9; p. 104036
• Main Authors: Golub, Ilana S., Manubolu, Venkat S., Aldana-Bitar, Jairo, Dahal, Suraj, Verghese, Dhiran, Alalawi, Luay, Krishnan, Srikanth, Kianoush, Sina, Benzing, Travis, Ichikawa, Keishi, Kinninger, April, Fazlalizadeh, Hooman, Pourafkari, Leili, Ahmad, Khadije, Susarla, Shriraj, Mangaoang, Czarina, Ghanem, Ahmed K., Javier, Denise Alison, Hamal, Sajad, Roy, Sion K., Budoff, Matthew J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2025
• Subjects: Adiposity - drug effects; Aged; Atherosclerotic cardiovascular disease (ASCVD); Cardiovascular disease (CVD); computed tomography; Computed tomography angiography (CTA); Coronary artery calcium (CAC); coronary artery disease; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - etiology; Coronary Artery Disease - prevention & control; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; fatty liver; Fatty Liver - diagnostic imaging; Fatty Liver - drug therapy; Female; GLP1 receptor agonists; Glucagon-Like Peptide 1; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - therapeutic use; Hepatocellular carcinoma (HCC); Humans; hyperlipidemia; hypertension; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; lipid content; liver; Liver - diagnostic imaging; Liver - drug effects; Male; males; Metabolic dysfunction-associated steatohepatitis (MASH); Metabolic dysfunction-associated steatotic liver disease (MASLD); metabolism; Middle Aged; mortality; noninsulin-dependent diabetes mellitus; nutrition; placebos; Predictive Value of Tests; randomized clinical trials; Randomized trial; regression analysis; risk factors; Semaglutide; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Computed tomography angiography (CTA); Metabolic dysfunction-associated steatohepatitis (MASH); Hepatocellular carcinoma (HCC); Semaglutide; GLP1 receptor agonists; Randomized trial; Atherosclerotic cardiovascular disease (ASCVD); Metabolic dysfunction-associated steatotic liver disease (MASLD); Coronary artery calcium (CAC); Cardiovascular disease (CVD)

The prevalence of hepatic steatosis continues to increase worldwide. Hepatic steatosis is increasingly recognized as an independent risk factor for cardiovascular mortality. However, there are limited options for the treatment of fatty liver. In this study, we evaluated the effect of semaglutide on...